Results 41 to 50 of about 105,016 (295)

Membranous nephropathy associated with fluconazole treatment.

, 2007
About 6% to 9% of cases of membranous nephropathy develop secondary to exposure to drugs. Fluconazole is a widely used antifungal agent that was never implicated in the development of membranous nephropathy.
Kim, H, Shin, GT, Jieun Park, Gyu-Tae Shin, Heungsoo Kim, Hyunee Yim, Park, J, Yim, H   +7 more
core   +1 more source

Idiopathic membranous nephropathy preceding membranous lupus nephritis: a case report

, 2020
Membranous nephropathy is one of the most common causes of nephrotic syndrome in the adult population. According to the underlying etiology, membranous nephropathy is classified as either primary or secondary.
Kurultak, I., Dogan, A. F., Usta, U., Ustundag, S., Aygun, G., Gokalp, C.   +5 more
core   +1 more source

Treatment with rituximab in idiopathic membranous nephropathy [PDF]

, 2016
Rituximab represents a valid therapeutic option to induce remission in patients with primary glomerulonephritis. Despite several studies proving its efficacy in improving outcomes in patients with membranous nephropathy (MN), its role in therapeutic ...
Tondolo, Francesco, Bruno, Francesca, GESUALDO, Loreto, Grandaliano G., Grandaliano, Giuseppe, Fiorentino, Marco, MANNO, Carlo, Infante, Barbara   +7 more
core   +1 more source

USP30‐Mediated Deubiquitination of PEX5 Suppresses Pexophagy to Drive Tubular Injury in Diabetic Kidney Disease

Advanced Science, EarlyView.
USP30 accumulation in diabetic renal tubular epithelial cells deubiquitinates PEX5, suppresses pexophagy, and drives dysfunctional peroxisome accumulation and tubular injury. USP30 depletion restores PEX5 ubiquitination and pexophagy, improves peroxisomal function, and alleviates tubular damage, highlighting USP30 as a therapeutic target in diabetic ...
Jia Li, Chaoyang Hua, Guangpu Li, Furong Zhai, Jingjing Ren, Shaokang Pan, Qi Feng, Jianguo Wen, Dongwei Liu, Zhangsuo Liu, Jiayu Duan   +10 more
wiley   +1 more source

Clinical, genetic and molecular aspects of membranous nephropathy [PDF]

, 2011
Membranous Nephropathy (MN) is one of the leading causes of end-stage renal disease (ESRD). MN is an autoimmune disease in which autoantibodies target antigens at the level of the glomerular basement membrane.
Stanescu, H.C.
core  

Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial

, 2021
A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is ...
Marcantoni C., Marisa Santostefano, Sandro Feriozzi, Pani, Antonello, Domenico, Santoro, Passerini, Patrizia, Claudio Ponticelli, Nadia Dallera, Pani A., Passerini P., Antonello Pani, Mani L. -Y., Carmelita Marcantoni, Pietro Ravani, Gesualdo L., Federico Alberici, Boscutti G., Marco Quaglia, Mani, Laila-Yasmin, Quaglia M., Feriozzi, Sandro, Ghiggeri G. M., Francesco Scolari, Angelo Ferrantelli, Patrizia Passerini, Ghiggeri, Gian Marco, Laila-Yasmin Mani, Quaglia, Marco, Ponticelli C., Magistroni, Riccardo, Santostefano M., Ravani P., Domenico Santoro, Alberici F., Marcantoni, Carmelita, Dallera N., Elisa Delbarba, Gian Marco Ghiggeri, Scolari, Francesco, Santoro, Domenico, Delbarba E., Santoro D., Delbarba, Elisa, Feriozzi S., Riccardo Magistroni, Ponticelli, Claudio, Loreto Gesualdo, Ferrantelli A., Boscutti, Giuliano, Santostefano, Marisa, Gesualdo, Loreto, Giuliano Boscutti, Dallera, Nadia, Alberici, Federico, Scolari F., Magistroni R., Ferrantelli, Angelo, Ravani, Pietro   +57 more
core   +1 more source

Klotho‐Derived Peptide 1 Protects against Acute Kidney Injury by Directly Targeting Mitochondrial ATAD3A

Advanced Science, EarlyView.
This study uncovers that KP1, a Klotho‐derived peptide, protects the kidney against acute kidney injury, a clinical syndrome with high morbidity and mortality. KP1 enters tubular epithelial cells via endocytosis, directly interacts with the mitochondrial ATAD3A/HIGD2A complex, thereby preventing cytochrome c release, and caspases activation, and ...
Xiaoyao Zhang, Shihui Lin, Tianyu Wu, Zhixin Zhang, Hong Zhou, Xue Hong, Youhua Liu   +6 more
wiley   +1 more source

Alternative Pathway Is Essential for Glomerular Complement Activation and Proteinuria in a Mouse Model of Membranous Nephropathy

Frontiers in Immunology, 2018
Membranous nephropathy is an immune kidney disease caused by IgG antibodies that form glomerular subepithelial immune complexes. Proteinuria is mediated by complement activation, as a result of podocyte injury by C5b-9, but the role of specific ...
Wentian Luo, Wentian Luo, Florina Olaru, Florina Olaru, Jeffrey H. Miner, Laurence H. Beck, Johan van der Vlag, Joshua M. Thurman, Dorin-Bogdan Borza, Dorin-Bogdan Borza   +9 more
doaj   +1 more source

Case Report: Membranous Nephropathy Secondary to Cobalamin C Disease

Frontiers in Medicine, 2022
BackgroundMutation of MMACHC causes inherited cobalamin C disease with methylmalonic academia (MMA) and homocysteinemia. Renal complications may also be present in patients with this deficiency.
Qiang Wang, Qi Wang, Yanxia Gao, Chenquan Tang, Zhaoli Gao, Zhao Hu   +5 more
doaj   +1 more source

THSD7A Exacerbates Atherosclerosis via Activation of Signaling Axis αvβ3/CEBPD/IL1A

Advanced Science, EarlyView.
THSD7A exerts pro‐inflammatory effects and exacerbates atherosclerosis. Mechanistically, THSD7A regulates endothelial cell inflammation and atherosclerosis by activating the αvβ3/CEBPD/IL1A signaling axis. THSD7A is not only a genetic marker but also a potential therapeutic target for coronary artery disease (CAD).
Jiankun Liu, Hongfei Liu, Yiqi Wan, Andong Wu, Jiayu Qiu, Xueting Gong, Ya Zhao, Yuanyuan Li, Bingbing Zhou, Yangyi Zheng, Fang Wu, Yuanzheng Zhu, Weixin Lv, Xueer Li, Qiang Yuan, Xiao‐Li Tian   +15 more
wiley   +1 more source